Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02LVZ
|
|||
| Former ID |
DAP000800
|
|||
| Drug Name |
Darbepoetin alfa
|
|||
| Synonyms |
Aranesp (TN)
Click to Show/Hide
|
|||
| Indication | Anemia [ICD-11: 3A00-3A9Z; ICD-9: 280-285] | Approved | [1] | |
| Therapeutic Class |
Antianemic Agents
|
|||
| Company |
Amgen Inc
|
|||
| ADReCS Drug ID | BADD_D00583 | |||
| SuperDrug ATC ID |
B03XA02
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Erythropoietin Receptor (EPOR) | Target Info | Agonist | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| PI3K-Akt signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Pathway Interaction Database | Signaling events mediated by Stem cell factor receptor (c-Kit) | |||
| EPO signaling pathway | ||||
| WikiPathways | EPO Receptor Signaling | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84. | |||
| REF 2 | A cytosolic domain of the erythropoietin receptor contributes to endoplasmic reticulum-associated degradation. Eur J Biochem. 1999 Jul;263(2):410-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.